Drug Trial Radar · NCT05215418
A Study of VI-0521 on Ambulatory Blood Pressure (ABPM) in Overweight or Obese Subjects
Last checked: Nov 20, 2026Latest source record: Jul 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
565
Actual
Start
Jan 25, 2022
Primary completion
Apr 11, 2023
Study completion Apr 17, 2023
Sponsor
- Lead sponsor
- VIVUS LLCIndustry
- Sponsor type
- Industry
- First posted
- Jan 31, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is being conducted to evaluate the effect of VI-0521 (Qsymia®) on blood pressure as measured by 24-hour ambulatory blood pressure monitoring, compared to both placebo and an active control (phentermine 30 mg).
Conditions
- Blood Pressure
Interventions
VI-0521Drug
Phentermine/Topiramate Top Dose 15 mg/92 mg capsule
PhentermineDrug
Phentermine 30 mg capsule
PlaceboDrug
Inactive oral capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline to Week 8 in Mean Systolic Blood Pressure as Measured by 24-hr ABPMTime frame: Baseline to Week 8
Locations
28 sites in 1 country. Site status is shown where the registry gives one.
Clinical Site
Anniston, Alabama
Clinical Site
Mobile, Alabama
Clinical Site
Lincoln, California
Clinical Site
Long Beach, California
Clinical Site
Sacramento, California
Clinical Site
Spring Valley, California
Clinical Site
Upland, California
Clinical Site
Washington D.C., District of Columbia
Clinical Site
Coral Gables, Florida
Clinical Site
Miami, Florida
Clinical Site
Port Orange, Florida
Clinical Site
Brownsburg, Indiana
Clinical Site
Evansville, Indiana
Clinical Site
Wichita, Kansas
Clinical Site
Lexington, Kentucky
Clinical Site
Louisville, Kentucky
Clinical Site
Baton Rouge, Louisiana
Clinical Site
Kansas City, Missouri
Clinical Site
Butte, Montana
Clinical Site
Cary, North Carolina
Clinical Site
Eugene, Oregon
Clinical Site
Columbia, South Carolina
Clinical Site
Knoxville, Tennessee
Clinical Site
Friendswood, Texas
Clinical Site
North Richland Hills, Texas
Clinical Site
San Antonio, Texas
Clinical site
Salt Lake City, Utah
Clinical Site
Norfolk, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.